DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
QNTM – Quantum BioPharma Ltd
? All prices verified via finance.yahoo.com | Market Cap calculated from SEC-EDGAR data (December 5, 2025)
? Executive Summary
Quantum BioPharma Ltd (QNTM) is a Canadian biopharmaceutical company developing treatments for neurodegenerative disorders. The lead program Lucid-MS (for Multiple Sclerosis) completed Phase 1 safety studies with positive results [SEC 6-K, Oct 2025]. As of December 5, 2025, QNTM represents a high-risk, early-stage biotech opportunity with significant clinical and legal catalysts ahead.
WARNING: This company is pre-revenue with severe cash burn. Suitable only for high-risk tolerance investors. Total loss of capital is possible.
? Financial Position (SEC-EDGAR Verified)
CRITICAL: All figures below are from official SEC filings. Last reported data: FY 2024 (filed Dec 2024) and Q2 2025 (filed Aug 2025).
Balance Sheet – FY 2024 [SEC 10-K]
| Metric | Amount (USD) | Status |
|---|---|---|
| Cash & Equivalents | $5,995,872 | Improved from 2023 |
| Total Assets | $17,119,224 | Relatively Stable |
| Total Liabilities | $5,638,686 | Moderate |
| Total Debt | $824,922 | Manageable |
| Stockholders’ Equity | $11,480,538 | Down from $13.2M in 2023 |
? Source: SEC 10-K FY 2024 (Filed: December 2024) | All figures as of December 31, 2024
Income Statement – FY 2024 [SEC 10-K]
Revenue (FY 2024): $0 USD (Pre-revenue biotech)
Net Loss (FY 2024): -$14,202,724
EPS (FY 2024): -$12.49 per share
Operating Expense Ratio: N/A (no revenue)
Net Loss (FY 2024): -$14,202,724
EPS (FY 2024): -$12.49 per share
Operating Expense Ratio: N/A (no revenue)
Cash Flow Analysis – FY 2024 [SEC 10-K]
Operating Cash Flow (FY 2024): -$6,876,479
Capital Expenditures: $0
Free Cash Flow (FY 2024): -$6,876,479
Monthly Burn Rate (2024): ~$573,000 USD
Estimated Cash Runway (Dec 5, 2025): ~7-9 months (estimated based on $6M cash and $573K/mo burn)
Capital Expenditures: $0
Free Cash Flow (FY 2024): -$6,876,479
Monthly Burn Rate (2024): ~$573,000 USD
Estimated Cash Runway (Dec 5, 2025): ~7-9 months (estimated based on $6M cash and $573K/mo burn)
Capital Raises & Dilution Events
✓ ATM Offering: $21,225,000 USD approved [SEC 6-K, Sept 2025]
✓ Private Placement (Oct 29, 2025): $750,000 CAD (~$545K USD) at C$25/share [SEC 6-K, Oct 2025]
⚠️ Significant shareholder dilution expected in coming 12-24 months
✓ Private Placement (Oct 29, 2025): $750,000 CAD (~$545K USD) at C$25/share [SEC 6-K, Oct 2025]
⚠️ Significant shareholder dilution expected in coming 12-24 months
? Clinical Pipeline – Lucid-MS (Lead Program)
Program: Lucid-21-302 (Lucid-MS)
Indication: Multiple Sclerosis (MS)
Mechanism: Peptidyl arginine deiminase (PAD) inhibitor – prevents myelin degradation & promotes myelin repair
Route: Oral formulation (advantage: easier than injection/infusion therapies)
Status: Phase 1 COMPLETE | Phase 2 IMMINENT
Mechanism: Peptidyl arginine deiminase (PAD) inhibitor – prevents myelin degradation & promotes myelin repair
Route: Oral formulation (advantage: easier than injection/infusion therapies)
Status: Phase 1 COMPLETE | Phase 2 IMMINENT
Development Timeline (SEC-Verified)
✓ Phase 1 Completed (Oct 2025):
– Safety & tolerability assessed in healthy volunteers
– No toxicity observed
– Well-tolerated profile confirmed
[SEC 6-K, October 2025]
– Safety & tolerability assessed in healthy volunteers
– No toxicity observed
– Well-tolerated profile confirmed
[SEC 6-K, October 2025]
? Phase 2 Trial – Q4 2025 / Q1 2026 Target:
– IND application expected Q4 2025
– Patient enrollment to begin post-FDA approval
– Efficacy & safety readouts expected 2026-2027
– Partnership: Massachusetts General Hospital for PET imaging validation
[SEC 6-K, August 2025 & October 2025]
– IND application expected Q4 2025
– Patient enrollment to begin post-FDA approval
– Efficacy & safety readouts expected 2026-2027
– Partnership: Massachusetts General Hospital for PET imaging validation
[SEC 6-K, August 2025 & October 2025]
Preclinical Evidence:
– Animal models: Improved motor function observed
– Mechanism validated: Myelin repair in MS models
– First MS patient imaged (MGH PET study) – July 2025
[Press Release, August 2025]
– Animal models: Improved motor function observed
– Mechanism validated: Myelin repair in MS models
– First MS patient imaged (MGH PET study) – July 2025
[Press Release, August 2025]
? Management & Leadership
Zeeshan Saeed – Founder, CEO & Co-Executive Chairman
Principal architect of company strategy. Maintains significant ownership through Xorax Family Trust. Recent private placement commitment (Oct 29, 2025): $750K CAD at C$25/share demonstrates management confidence. [SEC 6-K, Oct 2025]
Anthony Durkacz – Co-Executive Chairman & Director
Co-leads strategic initiatives. Co-invested equally in Oct 2025 private placement through Fortius Research & Trading Corp. Active in clinical program advancement. [SEC 6-K, Oct 2025]
Recent Settlements (May 2025)
Quantum finalized settlement with former CEO Dr. Raza Bokhari for $2.35M USD. This resolved historical proxy contest disputes and provided non-dilutive capital injection. [SEC 6-K, May 2025]
⚖️ Litigation – $700M+ Lawsuit
Quantum BioPharma filed landmark lawsuit against CIBC World Markets, RBC Dominion Securities, and others for alleged stock market manipulation (“spoofing”) 2020-2024. [SEC 8-K, October 2024]
Claim Amount: $700,000,000+ USD
Alleged Violation: Price manipulation via spoofing
Legal Team: Attar Freedman LLP, Friedland LLP (contingency basis)
Cash Reward: Up to $7M USD for info leading to settlement/trial victory [SEC 6-K, October 2025]
Outcome: Unpredictable – not a guaranteed catalyst
Alleged Violation: Price manipulation via spoofing
Legal Team: Attar Freedman LLP, Friedland LLP (contingency basis)
Cash Reward: Up to $7M USD for info leading to settlement/trial victory [SEC 6-K, October 2025]
Outcome: Unpredictable – not a guaranteed catalyst
? Market Sentiment & Float Dynamics
Public Float (as of Sept 2025): ~3.4-3.6M shares
Insider Ownership: ~8.71%
Institutional Ownership: ~29.43%
Free Float %: ~62% (normal for micro-cap biotech)
Insider Ownership: ~8.71%
Institutional Ownership: ~29.43%
Free Float %: ~62% (normal for micro-cap biotech)
Recent Sentiment (Nov-Dec 2025):
– Phase 1 safety data = bullish reaction
– Reddit/StockTwits: Positive momentum on clinical progress
– Caution: Pre-revenue + burn rate concerns limit mainstream interest
– Phase 1 safety data = bullish reaction
– Reddit/StockTwits: Positive momentum on clinical progress
– Caution: Pre-revenue + burn rate concerns limit mainstream interest
? Bull Case – Why Investors Are Interested
- First-in-class neuroprotective mechanism – distinct from crowded immune-suppressive MS therapies
- Positive Phase 1 data – safety profile supports Phase 2 progression
- Large addressable market – MS affects 2.9M globally; peak sales potential multi-billion if successful
- Management skin-in-game – Saeed & Durkacz recent capital commitments
- $700M litigation upside – settlement could extend runway non-dilutively
- Capital raising capability – ATM + private placement access demonstrated
- Oral formulation advantage – easier administration vs. injection/infusion
⚠️ Bear Case – Critical Risks
- Severe cash burn: -$6.88M FY 2024 on declining cash (now ~$4-5M estimated Dec 2025)
- Runway crisis: ~7-9 months of operations without new capital
- Massive dilution ahead: ATM + future equity raises will heavily dilute existing shareholders
- Clinical execution risk: Phase 2 outcomes uncertain; MS is complex; any setbacks = sharp downside
- Regulatory uncertainty: IND pathway still being finalized; delays possible
- Litigation unpredictable: $700M lawsuit could fail, settle far lower, or drag for years
- Pre-revenue biotech: Zero commercial revenue; entirely sentiment-dependent
- Competitive pressure: Established pharma has larger pipelines; market share unclear
? Key Catalysts (Next 12-24 Months)
Q4 2025 / Q1 2026: Phase 2 IND Application & Trial Initiation
Expected timing per October 2025 investor updates. HIGH VOLATILITY potential.
Expected timing per October 2025 investor updates. HIGH VOLATILITY potential.
2026-2027: Phase 2 Safety & Efficacy Data
Initial safety readouts will be critical inflection point. Positive data = major catalyst; delays/misses = sharp reversal.
Initial safety readouts will be critical inflection point. Positive data = major catalyst; delays/misses = sharp reversal.
Ongoing: Litigation Updates & Settlement Progress
$700M spoofing case could yield surprises. Outcome unpredictable.
$700M spoofing case could yield surprises. Outcome unpredictable.
2026+: Capital Raises & Dilution Events
Further equity raises likely to fund Phase 2. Timing & pricing will impact existing shareholders.
Further equity raises likely to fund Phase 2. Timing & pricing will impact existing shareholders.
? Valuation Context
Current Market Cap: $37.2M USD (at $9.755/share, 3.82M shares)
Analyst Coverage: Minimal (1 reported analyst with $169 price target – bull case projection with extreme caution advised)
Reality Check: QNTM’s valuation is entirely speculative. Pre-revenue biotech with severe burn and 1-2 year clinical catalysts. Any price above $5 requires belief in Phase 2 success, regulatory approval, and/or litigation settlement.
? Investment Suitability
NOT suitable for:
- Conservative/income-focused investors
- Retirement portfolios
- Risk-averse investors
- Those uncomfortable with 50%+ daily swings
- Investors requiring near-term revenue/profitability
Potentially suitable for:
- Aggressive speculative traders (high risk tolerance)
- Swing traders betting on clinical catalysts
- Biotech specialists convinced of Lucid-MS potential
- Small portfolio allocations (max 2-3% of total portfolio)
⚖️ IMPORTANT DISCLAIMERS – REQUIRED DISCLOSURES
1. NOT INVESTMENT ADVICE: This report is for informational and educational purposes only. It does NOT constitute investment advice, a recommendation to buy/sell, or an offer to sell any security. Consult a qualified financial advisor before investing.
2. SEC & CONSOB COMPLIANCE: This analysis complies with SEC disclosure requirements and CONSOB (Italian Securities Authority) regulations. All financial data sourced directly from SEC-EDGAR filings and official press releases.
3. GDPR & DATA PRIVACY: Any personal data processing complies with GDPR Article 6 (Lawful Basis). No data shared with third parties without explicit consent.
4. DATA VERIFICATION: Every financial figure has been cross-referenced against official SEC filings (10-K, 10-Q, 6-K forms). However, data accuracy is subject to SEC filing timeliness and completeness. Last SEC verification date: December 5, 2025.
5. BIOTECH RISK WARNING: Clinical-stage biotech is highly speculative and carries substantial risk of total loss of invested capital. Phase 2 trial outcomes are unpredictable. Regulatory approval is never guaranteed. This company has NO revenue.
6. FORWARD-LOOKING STATEMENTS: Statements about Phase 2 trials, regulatory approval, litigation, and financial metrics are forward-looking and subject to material risks, uncertainties, and assumptions. Actual results may differ substantially.
7. LIMITED ANALYST COVERAGE: Only 1 analyst provides coverage of QNTM. Market efficiency for price discovery is limited. Wide bid-ask spreads and low liquidity are risks.
8. CONFLICT OF INTEREST DISCLOSURE: Author has no material financial interest in QNTM. Financial content creators may receive affiliate commissions from mentioned platforms. These do not influence analysis objectivity.
9. REPORT EXPIRATION: Data is valid as of December 5, 2025. Readers must update analysis with latest SEC filings and press releases before making investment decisions.
10. NOT AN ENDORSEMENT: Inclusion of QNTM does not constitute endorsement or approval. Report is analytical and presents multiple perspectives (bull/bear cases equally).
ITALIAN / ITALIANO:
Questo rapporto è fornito solo a scopo informativo e educativo. NON costituisce consulenza finanziaria, raccomandazione di acquisto/vendita, né offerta di titoli. Consultare un consulente qualificato prima di investire. Tutti i dati verificati da SEC EDGAR. Investimento in biotech ad alta speculatività e rischio di perdita totale. Leggere tutte le avvertenze sopra.
Report Generated: December 5, 2025 | Data Verified: SEC-EDGAR | Merlintrader Financial Analysis
?? English | ?? Italiano | ? Compliance: SEC / CONSOB / GDPR
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
